JSPRW Jasper Therapeutics, Inc.
Price Chart
Executive Summary
Jasper Therapeutics announced its Board has initiated a comprehensive review of strategic alternatives to maximize shareholder value, including potential sale of assets, licensing, merger, or orderly wind-down. The clinical-stage biotech with no approved products plans cost-saving measures to preserve cash. This signals potential distress and uncertainty over the company's future.
Actionable Insight
Traders should monitor for further announcements regarding potential transactions or wind-down details. JSPRW warrants are likely to be worthless if the company winds down, but could have some residual value in a sale or merger. Expect continued volatility.
Key Facts
- Board initiated comprehensive review of strategic alternatives including sale of assets, licensing, sale of company, merger, or orderly wind-down.
- Company will evaluate cost-saving measures to preserve cash.
- No defined timeline for the strategic review; no assurance any transaction will occur.
- Jasper is a clinical-stage biotech with no approved products; briquilimab is in Phase 2b/3 for CSU, CIndU, and asthma.
Financial Impact
No specific financial figures provided; the strategic review could result in a sale, merger, or wind-down, with potential for complete loss of equity value in a wind-down scenario.
Risk Factors
- Failure to consummate any strategic alternative could lead to further cash burn and potential going-concern issues.
- Orderly wind-down would likely result in zero value for common stockholders and warrant holders.
- Lack of timeline creates uncertainty; company may need additional funding before any transaction closes.
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-063157 |
| Document: ea029290901ex99-1.htm | 0001213900-26-063157 |
| Document: 0001213900-26-063157-index-headers.html | 0001213900-26-063157 |
| Document: 0001213900-26-063157-index.html | 0001213900-26-063157 |
| Document: 0001213900-26-063157.txt | 0001213900-26-063157 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 1, 2026
4d ago
|
8-K
| $0.0204 $0.0204 | · 0.00% | ▲ +0.14% | $0.0142 (+30.39%) |
|
May 21, 2026
14d ago
|
8-K
| — | awaiting T+1 | — | — |
|
May 14, 2026
21d ago
|
8-K
| — | awaiting T+1 | — | — |
|
Mar 30, 2026
9w ago
|
8-K
| $0.0204 $0.0204 | · 0.00% | ▼ −0.75% | $0.0142 (−30.39%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access